Disregulation of proopiomelanocortin and contagious maladaptive behavior

Regulatory Peptides

Volumn 108, Issue 2-3, 2002, Pages 179-185

  Sandman, Curt A ^a,b   Touchette, Paul ^b,c   Marion, Sarah ^a,b   Lenjavi, Mohammed ^a,b   Chicz Demet, Aleksandra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fairview Developmental Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACTH; Autism; Mental retardation; Self injury; Endorphin

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; PROOPIOMELANOCORTIN;

ARTICLE; AUTOMUTILATION; BEHAVIOR; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER; CONTROLLED STUDY; EVALUATION; GENE EXPRESSION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; MALADJUSTMENT; PHENOTYPE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0037107457     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00097-6     Document Type: Article

References (45)

1. Sato H., Mori S. Subregional assignment of the proopiomelanocortin gene (POMC) to human chromosome band 2p23.3 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 76:1997;221-222.
2. Seidah N.G., Chretien M. Proprotein and prohormone convertases of the subtilisin family. Trends Endocrinol. Metab. 3:1992;133-140.
3. Mains R.E., Eipper B.A. Peptides. Siegal G.J., Agranoff B.W., Albers R.W., Fisher S.K., Uhler M.D. Basic neurochemistry: molecular, cellular and medical aspects. 6th ed. 1999;363-382 Lipincott Williams & Wilkins Publishers, Philadelphia.
4. Mains R.E., Berard C.A., Denault J.B., Zhou A., Johnson R.C., Leduc R. PACE4: a subtilisin-like endoprotease with unique properties. Biochem. J. 321:1997;587-593.
5. Seidad N.G., Marcinkiewicz M., Bejannet S.et al. Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, KEX 2: distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2. Mol. Endocrinol. 5:1991;111-122.
6. Bertagna X. Proopiomelanocortin-derived peptides. Endocrinol. Metab. Clin. N. Am. 23:1994;467-485.
7. Boutillier A.L., Monnier D., Lorang D., Lundblad J.R., Roberts J.L., Loeffler J.P. Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Mol. Endocrinol. 9:1995;745-755.
8. Zheng M., Streck R.D., Scott R.E.M.et al. The development expression in rat proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity. J. Neurosci. 14:1994;4656-4673.
9. Bertagna X. Proopiomelanocortin-derived peptides. Endocrinol. Metab. Clin. N. Am. 23:1994;467-485.
10. Strand F.L. Neuropeptides: regulators of physiological process. 1999;MIT Press, Cambridge, MA.
11. Sandman C.A., Kastin A.J. Behavior actions of ACTH and related peptides. Li C.H. Hormonal proteins and peptides. 1987;147-171 Academic Press, New York.
12. Sandman C.A., Yessaian N. Persisting subsensitivity of the striatal dopamine system after fetal exposure to B-endorphin. Life Sci. 39:1986;1755-1763.
13. Beckwith W.et al. The influence of neonatal injections of a-MSH on learning, memory and attention in rats. Physiol. Behav. 18:1976;63-71.
14. Sandman C.A., Hetrick W.P., Taylor D.V.et al. Dissociation of POMC peptides after self-injury predicts response to centrally acting opiate blockers. Am. J. Ment. Retard. 102:1997;182-199.
15. Sandman C.A., Spence M.A., Smith M. Proopiomelanocortin (POMC) disregulation and response to opiate blockers. Ment. Retard. Dev. Disabil. Res. Rev. 5:1999;314-321.
16. Carr E.G. Emerging themes in the functional analysis of problem behavior. J. Appl. Behav. Anal. 27:1994;393-399.
17. Bouvard M.P., Leboyer M., Launay J.M.et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 58:1995;191-201.
18. Ernst M., Devi L., Silva R.R.et al. Plasma beta-endorphin levels, naltrexone and haloperidol in autistic children. Psychopharmacology Bulletin. 29:1993;221-227.
19. Gillberg C. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev. Med. Child Neurol. 37:1995;88-92.
20. LeBoyer M., Bouvard M.P., Recasens C.et al. Difference between plasma N- and C- terminally directed beta-endorphin immunoreactivity in infantile autism. Am. J. Psychiatry. 151:1994;1797-1801.
21. Leboyer M., Philippe A., Bouvard M.et al. Whole blood serotinin and plasma beta-endorphin in autistic probands and their first degree relatives. Soc. Biol. Psychiatry. 45:1999;158-163.
22. Sandman C.A., Barron J.L., Colman H. An orally administered opiate blocker, Naltrexone attenuates self-injurious behavior. Am. J. Ment. Retard. 95:1990;93-102.
23. Sandman C.A., Baron J.L., DeMet E.M., Chicz-DeMet A., Rothenberg S. Opiod peptides and development: clinical implications. Koob G.F., Sandman C.A., Strand F.L. A decade of neoropeptides, past, present and future. Ann. N.Y. Acad. Sci. 579:1990;91-107.
24. Sandman C.A., Hetrick W., Taylor D., Marion S., Chicz-DeMet A. Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury. Peptides. 21:2000;785-791.
25. Sandman C.A., Touchette P. Opiods and the maintenance of self-injurious behavior. Schroeder S.R., Oster-granite M.L., Thompson T. Self-injurious behavior: gene-brain-behavior relationships. 2002;191-204 American Psychological Association, Washington, D.C.
26. Sandman C.A., Hetrick W.P. Opiate mechanisms in self-injury. Ment. Retard. Dev. Disabil. Res. Rev. 1:1995;130-136.
27. Krude H., Biebermann H., Luck W.et al. Severe early-onset obesity, adrenal insufficient and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19:1998;155-157.
28. Cazzullo A.G., Musetti M.C., Musetti L., Bajo S., Sacerdote P., Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur. Neuropsycholopharmacol. 9:1999;361-363.
29. Crews W.D. Jr., Rhodes R.D., Bonaventura S.H., Rowe F.B., Goering A.M. Cessation of long-term naltrexone administration: longitudinal follow-ups. Res. Dev. Disabil. 20:1999;23-30.
30. Sandman C.A., Hetrick W.P., Taylor D.V.et al. Naltrexone reduces self-injury and improves learning. Exp. Clin. Psychopharmacol. 1:1993;242-258.
31. Willemsen-Swinkels S.H.N., Buitelaar J.K., van Berchelaer-Onnes I., van Engeland H. Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J. Autism Dev. Disabil. 29:1999;167-169.
32. White T., Schultz S.K. Naltrexone treatment for a 3-year-old boy with self-injurious behavior. Am. J. Psychiatry. 157:2000;1574.
33. Sandman C.A., Thompson T., Barrett R.P.et al. Opiate blockers. Aman M., Reiss S. Consensus handbook on psychopharmacology. 1998;291-302 Ohio State University, Columbus, OH.
34. Sandman C.A. The opiate hypothesis in autism and self-injury. J. Child Adolesc. Psychopharmacol. 1:1990/1991;235-246.
35. Sandman C.A. B-endorphin disregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis. Synapse. 2:1988;193-199.
36. Cataldo M.F., Harris J. The biological basis for self-injury in the mentally retarded. Anal. Intervent. Dev. Disabil. 2:1982;21-39.
37. Deutsch S.I. Rationale for the administration of opiate antagonists in treating infantile autism. Am. J. Ment. Retard. 90:1986;631-635.
38. Farber J.M. Psychopharmacology of self-injurious behavior in the mentally retarded. J. Am. Acad. Child Adolesc. Psych. 26:1987;296-302.
39. Davidson P.W., Kleene B.M., Caroll M.et al. Effects of naloxene of self-injurious behavior: a case study. Appl. Res. Ment. Retard. 4:1993;1.
40. Sandman C.A., Datta P., Barron J.L.et al. Naloxone attenuates self-abusive behavior in developmentally disabled clients. Appl. Res. Ment. Retard. 4:1983;5-11.
41. Scifo R., Cioni M., Nicolosi A., Batticane N., Tirolo C., Testa N.et al. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann. Ist. Super. Sanitá 32:1996;351-359.
42. Willemsen-Swinkles S.H.N., Buitelarr J.K., Nijhof G.J.et al. Failure of naltrexone to reduce self-injurious and autistic behavior in mentally retarded adults. Arch. Gen. Psychiatry. 52:1995;766-773.
43. Sandman C.A., Hetrick W.P., Taylor D.V., Marion S., Touchette P., Barron J.L.et al. Long-term effects of naltrexone on self-injurious behavior. Am. J. Ment. Retard. 105:2000;103-117.
44. Thompson T., Felces D., Symons F. Behavioral observations: technology and applications in developmental disabilities. 2000;Paul H. Brookes Publishing, Baltimore, MD.
45. Rodbard D., Munson P., De Lean A. Improved curve fitting, parallelism testing, characterization of sensitivity and specificity, validation and optimization for radioligand assays. Radioimmunoassay Relat. Proced. Med. 1:1978;469-504.